⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LGVN News
Longeveron Inc. Common Stock
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
globenewswire.com
LGVN
Form 8-K
sec.gov
LGVN
Longeveron to Present at BIO International Convention 2026
globenewswire.com
LGVNR
LGVN
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
globenewswire.com
LGVNR
LGVN
Form 8-K
sec.gov
LGVN
Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update
globenewswire.com
LGVN
Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
globenewswire.com
LGVN
Form 8-K
sec.gov
LGVN
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
globenewswire.com
LGVN
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
globenewswire.com
LGVN